Abramson Cancer Center - University of Pennsylvania (UPENN)
University of Pennsylvania
Philadelphia, PA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Accepting patients
KarMMa-9
Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
Learn more- CAR T Cell
- Immunomodulatory Drug
- BCMA
- Randomization
- Phase 3
Accepting patients
CARTITUDE-2
Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsNot yet accepting
MonumenTAL-8
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Learn more- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Phase 2
Accepting patients
Teclistamab
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 2
Accepting patients
Cevostamab after CAR-T Cell Therapy
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- FCRH5
- Phase 2
Accepting patients
CART 38
Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma
Learn more- CAR T Cell
- CD38
- Phase 1
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Learn more- BCMA
- GPRC5D
- Tri-specific Antibody
- Phase 1
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Not currently accepting
Cevostamab
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- FCRH5
- Phase 1
- Has results
Accepting patients
MajesTEC-1
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
Learn more- Bispecific Antibody
- BCMA
- Phase 1
- Has results